1606 Corporation (PK) (CBDW) News

Like I said, it's easy to talk smack when the stock is up and easy to be quiet as a church mouse when the stock is down

Adnexus Biotechnologies Inc. operates an advanced AI-driven drug discovery and development platform called SUTRA. This platform, at the forefront of technological innovation, identifies specific sites and biomarkers for infectious and neurological diseases. The AI platform has successfully produced Fully Human, Broadly Neutralizing, durable monoclonal antibodies unaffected by virus mutations. The AI platform utilizes a repository containing data on 19 viruses, a curated library of 8 million molecules, and human microbiome samples. The goal is to create robust models and make significant advancements in producing groundbreaking drugs that demonstrate effectiveness and disrupt the landscape of treatments for infectious and neurological diseases.

$CBDW Can do bigger move soon. Company blog https://cbdw.ai/blog/

Yikes

Ai CBDW - Blog https://cbdw.ai/chatbots-in-investor-relations-a-new-era-of-efficient-communication-and-how-1606-corp-cbdw-is-leading-the-way-on-the-otc/

$CBDW DD 1 day historical pattern.
https://postimg.cc/ykYq2rVb

$CBDW 0.039 a half way for 0.07 the recent pricing fall! Wedges build new pattern that looks similar, Something strong by indicators. Please include your knowledge support if telling negative.NO personal opinion imo. thank you buddy

See if we can crack 04's here today #LFG $CBDW

You're welcome

CBDW Pro team.

Your adding to conversation newbie.

Drug discovery :)

yep I agree, for now... flip while you can

Good looking scam widening. 1 minute chart up and continuously rocking.

Dr. SCAMdra buying all this up with his ENZC money lol

$CBDW The Road Ahead
As we look to the future, the role of AI in shaping industries and driving economic growth cannot be overstated. Companies that are early adopters of AI technologies and that demonstrate a commitment to innovation, like 1606 Corp, are poised to lead the way. With its strategic initiatives, low PPS, and innovative AI solutions, 1606 Corp is well-positioned to thrive in the coming wave of AI stocks.

$CBDW widening on pattern, positively rocking on indicators, Negative talkers showing a bold scripted intension..
CBDW blog support must read!! https://cbdw.ai/the-future-of-ai-and-1606-corps-position-in-the-coming-wave-of-ai-stocks/

1606 Corp. (OTC: CBDW) Investor Group Call
Join CEO Austin Lambrecht, for a presentation and live Q&A session. Learn about 1606 Corp.'s innovative solutions for the high-growth, multi-billion-dollar AI industry, strong market positioning, and commitment to sustainable and ethical business practices.
Event information:

When October 10, 2024 4:15 PM Eastern Time (US and Canada)

$CBDW Must watch Video: Adnexus #Biotechnologies Partners with 1606 Corp. for Strategic Investment to Revolutionize AI-Driven Drug Discovery

Who is Adnexus #biotech? Check this out.

#AI #healthcare #HealthcareInnovation #Wellness

Link: youtube.com/shorts/mKqaYwRgGK4?si=f9mRv08GqqUIPUzB

Good morning, Possible 3 days uptrend to break MA 200. Strong support by indicators :)

Good Morning $CBDW

Trying to get .04's here $CBDW

$CBDW Looking great here today. Market reaction to news is strong and positive.

Bids building.. $CBDW

Take a look at the latest news this morning from the company.https://t.co/qne9GnhDRg— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) September 17, 2024

.0394 HOD .. close $CBDW

$CBDW 8-K out https://www.otcmarkets.com/filing/html?id=17839433&guid=dlL-k6M9NMreJth

Almost there.

.04's up next! $CBDW Low Float Monster!!

The #AI platform utilizes a repository containing data on 19 viruses, a curated library of 8 million molecules, and human microbiome samples. The goal is to create robust models and make significant advancements in producing groundbreaking drugs that demonstrate effectiveness and disrupt the landscape of treatments for infectious and neurological diseases.

AI-Driven Drug Discovery $CBDW

Dr. Gaurav Chandra, expressing his enthusiasm about the strategic partnership with 1606 Corp. and emphasizing its significance, stated, "We are thrilled to embark on this strategic partnership with 1606 Corp. Their commitment to leveraging AI technology aligns perfectly with our mission to drive breakthroughs in drug discovery and infectious disease treatment. This collaboration represents a significant opportunity to enhance our technological capabilities and expand the impact of our innovative solutions."

$CBDW @CBDWInc Huge news! Adnexus Biotechnologies Partners with 1606 Corp. for Strategic Investment to Revolutionize AI-Driven Drug Discovery https://finance.yahoo.com/news/adnexus-biotechnologies-partners-1606-corp-120000325.html

SEATTLE, WA / ACCESSWIRE / September 17, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606") is pleased to announce it has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research.

This potential strategic investment exemplifies 1606 Corp.'s commitment to advancing its technological capabilities and expanding its reach in the AI sector. Integrating Adnexus's cutting-edge AI research and development into its portfolio underscores 1606 Corp.'s aim to impact the AI sector, healthcare, and biotechnology significantly. This collaboration has the potential to push the boundaries of what is achievable in these fields.

Adnexus Biotechnologies Inc. operates an advanced AI-driven drug discovery and development platform called SUTRA. This platform, at the forefront of technological innovation, identifies specific sites and biomarkers for infectious and neurological diseases. The AI platform has successfully produced Fully Human, Broadly Neutralizing, durable monoclonal antibodies unaffected by virus mutations. The AI platform utilizes a repository containing data on 19 viruses, a curated library of 8 million molecules, and human microbiome samples. The goal is to create robust models and make significant advancements in producing groundbreaking drugs that demonstrate effectiveness and disrupt the landscape of treatments for infectious and neurological diseases.

Adnexus Biotechnologies' CEO, Gaurav Chandra, emphasizing Adnexus' unwavering dedication to advancing the frontiers of pharmaceutical development, stated, "Adnexus Biotechnologies Inc. is committed to pushing the boundaries of pharmaceutical development through its state-of-the-art AI platform, monoclonal antibodies, and HIV capsid inhibitor. The pre-clinical results of the HIV capsid inhibitor in combating HIV, and the Fully Human Monoclonal Antibody (Clone3), have become priced assets of Adnexus Biotechnologies' therapeutic portfolio. We are confident we will advance these molecules with the dedicated efforts of our team of accomplished scientists and executives with advanced chemistry, pharmacology, and drug development expertise." This dedication instills confidence in our ability to deliver impactful solutions.

Dr. Gaurav Chandra, expressing his enthusiasm about the strategic partnership with 1606 Corp. and emphasizing its significance, stated, "We are thrilled to embark on this strategic partnership with 1606 Corp. Their commitment to leveraging AI technology aligns perfectly with our mission to drive breakthroughs in drug discovery and infectious disease treatment. This collaboration represents a significant opportunity to enhance our technological capabilities and expand the impact of our innovative solutions."

Austen Lambrecht, CEO of 1606 Corp., commented, "We are pleased to enter into this agreement with Adnexus. Their pioneering work in AI-driven drug discovery and infectious disease treatment closely aligns with our commitment to leveraging advanced AI technologies to develop high-impact solutions. This collaboration significantly advances our efforts to diversify and strengthen our technological capabilities."

In order to close, the transaction must follow standard due diligence and fulfill certain conditions detailed in the LOI. Both companies are optimistic that this strategic partnership will deliver substantial shareholder value, drive technological advancements, and foster innovation in their respective fields. We will keep our stakeholders informed about the progress and any significant developments throughout the process.

GM haters, CBDW Closed up +35.00% :)

Enzolytics 2.0. Chandra the crook strikes again. CBDW is a scam.

They are piss poor traders that lost it all.. blame the company and other traders for their F- ups $CBDW

These low floaters move very fast $CBDW

$CBDW New HOD .0349 +48.51% http://cbdw.ai #AI #Sector

When bashing goes horribly wrong.. lmfao $CBDW 🤘

Still not a legit company lol, a flip at best

Learing to trade would help with $CBDW

How You Doin? +48% #Green #AI $CBDW

I'm talking about the stock lololzzz $CBDW

Gaurav Chandra the lying so-called “doctor” lol, scamming again here in CBDW.

Is your grass growing nicely?

Nice and GREEN $CBDW

Gaurav Chandra scam

$CBDW and Adnexus Leaders in Research & Development

Our company, Adnexus, has developed a unique and innovative approach to producing antibodies that target specific sites on viruses. This process involves using Artificial Intelligence to identify conserved and immutable targets, which we can then analyze for linearity, accessibility by antibodies, neutralizability, and the effect of mutations.

https://www.adnexusbiotech.com/research-development/

$CBDW looking hot this week imo.
chart https://schrts.co/xEsVWedJ